Rare diseases
Investigational molecules
Locations
Back to Hungary23 clinical trials in Farkasgyepu, Hungary. Every trial is listed in the EU Clinical Trials Register and updated daily.
Study on the Long-term Safety and Efficacy of Pembrolizumab and Lenvatinib for Patients with Advanced Tumors
HungaryStudy of LY3537982, pembrolizumab, and a drug combination for patients with advanced non-small cell lung cancer and a KRAS G12C mutation
HungaryPumitamig Versus Durvalumab in Patients With Unresectable Stage III Non-Small Cell Lung Cancer Without Progression After Chemoradiation
HungaryPumitamig Versus Pembrolizumab in Patients With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%
HungaryComparing sotorasib and pembrolizumab with chemotherapy for patients with advanced non-small cell lung cancer and a KRAS G12C mutation
HungaryA study of PF-08634404 and a drug combination in adults with advanced or metastatic non-small cell lung cancer
HungaryA Study of BMS-986504 with Drug Combination Compared to Placebo with Drug Combination in Patients with Advanced Non-Small Cell Lung Cancer Starting First Treatment
HungaryStudy comparing GSK5764227 and topotecan in adults with relapsed small cell lung cancer
HungaryStudy comparing QL2107 and pembrolizumab in patients with resected non-small cell lung cancer receiving adjuvant therapy
HungaryStudy of Sigvotatug Vedotin and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with High PD-L1 Levels
HungaryStudy of Adagrasib with Pembrolizumab and Chemotherapy for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation
HungaryStudy of Adagrasib Alone and with Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with KRAS G12C Mutation
HungaryThe busiest research cities in the country
What the registry says about research in the country
Innovative clinical trials exploring immunotherapy combinations for advanced non-small cell lung cancer (NSCLC), focusing on treatment options for patients with various stages of the disease.
Research aims to improve survival rates and treatment outcomes through targeted immunological approaches.
Studies evaluating targeted therapies for specific mutations in non-small cell lung cancer, including HER2 and KRAS G12C mutations.
Investigations focus on personalized treatment strategies for different NSCLC subtypes.
Clinical trials examining new therapeutic options for small cell lung cancer, including novel drug combinations and comparative effectiveness studies.
Research focuses on improving treatment options for patients with relapsed SCLC.
Tell us about your condition – we search every trial in Europe and connect you with the right site.
